Back HCV Treatment

Sofosbuvir/Ledipasvir Cures 100% of Genotype 1 Hepatitis C Patients in Japanese Study

All treatment-naive and previously treated participants using a combination pill containing Gilead Science's hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (Sovaldi) and NS5A inhibitor ledipasvir, without ribavirin, for 12 weeks achieved sustained virological response in a Phase 3 study in Japan, where most hepatitis C patients have HCV genotype 1b.


Read more: